Skip to main content

Advertisement

SpringerLink
Log in

Comparison of five different antibodies in the immunohistochemical assay of estrogen receptor α in Human breast cancer

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

Estrogen receptor α(ER) expression is the best prognostic and predictive factor of hormone dependency of human breast cancers. Unlike enzyme immunoassay (EIA), which has been widely used to evaluate ER status in breast cancer, immunohistochemical assay (IHC) can detect ER in a small amounts of tissue with detailed localization. Although there is a sufficient number of ER antibodies against various regions of the protein, the reliability of IHC staining is only well understood for a few. IHC and EIA for the evaluation of the ER status of human breast cancer, therefore, should be compared using the same breast cancer tissues.

Methods

Five different ER antibodies (1D-5, C-314, G-20, C-311 and HC-20) that identify different amino acid sequences were used. The evaluation of ER status by IHC using these antibodies was compared with EIA concomitantly in 97 primary human breast cancer tissues.

Results

The positiviry rate for EIA was 68%. That of IHC for antibodies 1D-5, C-314, G-20, C-311 and HC-20 was 50.5%, 47.4%, 46.4%, 44.3% and 57.7%, respectively. The concordance between EIA was 76.3% for 1 D-5 and 77.3% for HC-20, which is statistically highly significant (p<0.0001); Other antibodies were not.

Conclusions

HC-20 is most suitable in the evaluation of the ER status of human breast cancers using the IHC method. Although antibody 1 D-5 is also available, C-314, G20 and C-311 are unreliable in such an evaluation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

ER:

Estrogen receptor α

EIA:

Enzyme immunoassay

IHC:

Immuno-histochemical assay

References

  1. McGuire WL: Breast cancer prognostic factors; Evaluation guidelines. J Natl Cancer Inst :154–155, 1991.

  2. Early Breast Cancer Trials Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy.Lancet 339:1–15, 71-85, 1992.

    Google Scholar 

  3. ASCO tumor marker expert panel: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer.J Clin Oncol 14:2843–2877, 1996.

    Google Scholar 

  4. Fisher B, Dignam J, Bryant J,et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.J Natl Cancer Inst 88:1526–1542, 1996.

    Article  Google Scholar 

  5. Early Breast Cancer Trials Collaborative Group: Tamoxifen for early breast cancer; An overview of the randomised trials.Lancet 351:1451–1467, 1998.

    Article  Google Scholar 

  6. Frigo B, Pilotti S, Zurrida S,et al: Analysis of estrogen and progesterone receptors of preoperative fineneedle aspirates.Breast Cancer Res Treat 33:179–184, 1995.

    Article  PubMed  CAS  Google Scholar 

  7. Barnes DM, Harris WH, Smith P,et al: Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients.Br J Cancer 74:1445–1451, 1996

    PubMed  CAS  Google Scholar 

  8. Golouh R, Vrhovec I, Bracko M,et al: Comparison of standardized immunohistochemical assays for estrogen and progesterone receptor in breast carcinoma.Pathol Res Pract 193:543–549, 1997.

    PubMed  CAS  Google Scholar 

  9. Molino A, Micciolo R, Turazza M,et al: Prognostic significance of estrogen receptor in 405 primary breast cancers; A comparison of immunohistochemical and biochemical methods.Breast Cancer Res Treat 45:241–249, 1997.

    Article  PubMed  CAS  Google Scholar 

  10. Harvey JM, Clark GM, Osborne CK,et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.J Clin Oncol 17:1474–1481, 1999.

    PubMed  CAS  Google Scholar 

  11. Tora L, White J, Brou C,et al: The human estrogen receptor has two independent nonacidic transcriptional activation functions.Cell 59:477–487, 1989.

    Article  PubMed  CAS  Google Scholar 

  12. Danielian PS, White R, Lees JA,et al: Identification of a conserved region required for hormone dependent transcription activation by steroid hormone receptors.EMBOJ 11:1025–1033, 1992.

    CAS  Google Scholar 

  13. Allred DC, Clark GM, Elledge R,et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.J Natl Cancer Inst 85:200–206, 1993.

    Article  PubMed  CAS  Google Scholar 

  14. Iwase H, Omoto Y, Iwata H,et al: Genetic and epigenetic alterations of the estrogen receptor gene and hormone independence in human breast cancer.Oncology 55 (Suppl 1):ll-6, 1998.

    Google Scholar 

  15. Leygue E, Hall RE, Dotzlaw H,et al: Oestrogen receptor-alpha variant mRNA expression in primary human breast tumors and matched lymph node metastases.Br J Cancer 79:678–683, 1999.

    Article  Google Scholar 

  16. Chusacultanachai S, Glenn KA, Rodriguez AO,et al: Analysis of estrogen receptor element binding by genetically selected steroid receptor DNA binding domain mutants exhibiting altered specificity and enhanced affinity.J Biol Chem 274:23591–23598, 1999.

    Article  PubMed  CAS  Google Scholar 

  17. Traish AM, al-Fadhli S, Kounine M,et al: Identification of structurally altered estrogen receptors in human breast cancer by site-directed antibodies.Steroids 60:467–474, 1995.

    Article  PubMed  CAS  Google Scholar 

  18. Omoto Y, Iwase H, Iwata H,et al: Expression of estrogen receptor α exon 5 and 7 deletion variant in human breast cancers.Breast Cancer 7:27–31, 2000.

    Article  PubMed  CAS  Google Scholar 

  19. Fritsch M, Leary CM, Furlow JD,et al: A ligand-induced conformational change in the estrogen receptor is located in the steroid binding domain.Biochemistry 31:5303–5311, 1992.

    Article  PubMed  CAS  Google Scholar 

  20. Traish AM, Pavao M: Binding of site-directed monoclonal antibodies to an epitope located in the A/B region (amino acids 140-154) of human estrogen receptor -induced conformational changes in an epitope in the DNA-binding domain.Steroids 61:549–556, 1996.

    Article  PubMed  CAS  Google Scholar 

  21. Baniahmad C, Nawaz Z, Baniahmad A,et al: Enhancement of human estrogen receptor activity by SPT6; A potent coactivator.Mol Endocrinol 9:34–43, 1995.

    Article  PubMed  CAS  Google Scholar 

  22. Webb P, Nguyen P, Shinsako J,et al: Estrogen receptor activation function 1 works by binding pl60 coactivator proteins.Mol Endocrinol 12:1605–1618, 1998.

    Article  PubMed  CAS  Google Scholar 

  23. Eng FC, Barsalou A, Akutsu A,et al: Different class of coactivators recognize distinct but overlapping binding sites on the estrogen receptor ligand binding domain.J Biol Chem 273:28371–28377, 1998.

    Article  PubMed  CAS  Google Scholar 

  24. Mak HY, Hoare S, Henttu PM,et al: Molecular determinants of the estrogen receptor-coactivator interface.Mol Cell Biol 19:3895–3903, 1999.

    PubMed  CAS  Google Scholar 

  25. al Saati T, Clamens S, Cohen-Knafo E,et al: Production of monoclonal antibodies to human estrogenreceptor protein (ER) using recombinant ER (RER).Int J Cancer 55:651–654, 1993.

    Article  PubMed  CAS  Google Scholar 

  26. Sannino P, Shousha S: Demonstration of estrogen receptor in paraffin wax sections of breast carcinoma using the monoclonal antibody 1D5 and microwave oven processing.J Clin Pathol 47:90–92, 1994.

    Article  PubMed  CAS  Google Scholar 

  27. Mauri FA, Caffo O, Veronese S,et al: Tissue carcinoembryonic antigen and oestrogen receptor status in breast carcinoma; an immunohistochemical study of clinical outcome in a series of 252 patients with longterm follow-up.Br J Cancer 77:1661–1668, 1998.

    PubMed  CAS  Google Scholar 

  28. Hori M, Iwasaki M, Yoshimi F,et al: Determination of estrogen receptor in primary breast cancer using two different monoclonal antibodies, and correlation with its mRNA expression.Pathol Int 49:191–197, 1999.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Higashi Municipal Hospital of Nagoya, Japan

    Shunzo Kobayashi & Yukashi Ito

  2. Department of Surgery, Nagoya City University Medical School, Japan

    Yoshiaki Ando, Yoko Omoto, Tatsuya Toyama & Hirotaka Iwase

Authors
  1. Shunzo Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yukashi Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoshiaki Ando
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoko Omoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tatsuya Toyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hirotaka Iwase
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Kobayashi, S., Ito, Y., Ando, Y. et al. Comparison of five different antibodies in the immunohistochemical assay of estrogen receptor α in Human breast cancer. Breast Cancer 7, 136–141 (2000). https://doi.org/10.1007/BF02967445

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02967445

Key words

Search

Navigation